Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).
JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Erscheinungsjahr: 2021
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Van Cutsem, Eric (Autor)
Singh, Prianka (Autor)
Cleary, James M. (Autor)
Kelly, Ronan Joseph (Autor)
Moehler, Markus H. (Autor)
Kuzdzal, Jaroslaw (Autor)
Mendez, Guillermo (Autor)
Motoyama, Satoru (Autor)
Elimova, Elena (Autor)
Grootscholten, Cecile (Autor)
Sun Xiaowu, ? (Autor)
Taylor, Fiona (Autor)
Lawrance, Rachael (Autor)
Padilla, Brad (Autor)
Moreno-Koehler, Alejandro (Autor)
Zhang, Jenny (Autor)
Blum, ? (Autor)
Ajani, Jaffer A. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
